have developed an algorithm that provides detailed operational NS. A sensitive and specific high-pressure liquid chromatograph-1 Criteria' for ra"king the probability of causation when an ADR isl kc system coupled to an electrochemical detector has been devel-(
I
. -~ ~~ --. ----n~~ . -----~ -. - have developed an algorithm that provides detailed operational NS. A sensitive and specific high-pressure liquid chromatograph-1 Criteria' for ra"king the probability of causation when an ADR isl kc system coupled to an electrochemical detector has been devel-(
Despite widespread epidemiological attention to surveillance for adverse drug reactions (ADR's), the results of surveys remain difficult to interpret because identification of ADR's has been a non-reproducible act of unspecified, subjective judgment.
To im~r0ve scientific orecision in the diarnosis of AnR's. we suspected. The algo;ithm provides a-scoring system for six axes of decision strategy: previous general experience with the drug, alternative etiologic candidates, timing, drug levels, and the effects of dechallenge and rechallenge. The sum of the scores is ordinally partitioned to rate the candidate ADR as definite, probable, possible, or unlikely. The reproducibility and validity of the algorithmic scores were tested with a clinical spectrum of 30 cases of suspected ADR's. Three physicians independently using the algorithm agreed completely in 20 cases; were within one ordinal category of each other in the remaining 10; and scored between 0.911 and 0.956 in the Cicchetti index of pair-wise agreement. The algorithm scorers' consensus agreed with 'truth', as defined by the implicit judgments of 2 experts, in 26 of 30 cases.
The algorithm provides a formal, valid, andreproduciblemethod of identifying the likelihood of an ADR, and can allow accurate assessment of this important, complex clinical phenomenon.
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Despite extensive clinical use, the basis for the antihyperalpha-methyldopa (a-MD) has remained undefined. pha-methyldopamine (a-MDA), the decarboxylated product of a-MD, as a possible mediator of these effects in the oped for the assay of a-MD, its metabolites and their sulfated conjugates in biological specimens. This technique has routinely detected 0.1 pg/ml of aromatic amine. In 7 hypertensive pediatri~ patients receiving a-MD therapy, the serum levels of a-MD and it: 3-0-SO4 Sonjugate were significantly elevated in subjects with impaired renal function (creatinine>2.0). The presence of a-MDA and its 3-0-504 conjugate has also been demonstrated in serum.
In renal dysfunction there is a 6-10 fold elevation of both a-MD, and its sulfated conjugate. The ratio a-MDA-3-0-S04:a-MDA (7-10) is significantly higher than the comparable a-MD-3-0-S04:a-MD ratio (2-4) in all patients. The accumulation of the presynaptic slly-active a-MDA and its sulfated conjugate in hypertensive patients with renal dysfunction may modify the response of these patients to a-MD. Studies in progress will attempt to define the mechanism of action of a-MD and relate its therapeutic effective ness to metabolic products of this agent. (Supported by USPHS firant llHD-08580). Phenobarbital has long been the drug of choice in controlling seizures and narcotic abstinence syndrome (NAS) in newborns. This report describes the relationship between dosage and serum concentration using a high oral loading dose of phenobarbital followed by maintenance dosing to provide therapeutic serum levels more rapidly than with previous methods. Twenty neonates born to narcotic dependent mothers were studied; all had NAS anc were evaluated by an abstinence scoring system. When high abstinence scores were reported (>8), all received a loading dose of 16 mg/kg of phenobarbital orally to rapidly achieve an expected therapeutic serum level of 18 mcglml. Results showed a serum level of 16 mcg/ml 2 2.6 at 3 hours after the loading dose as determined by the EMIT technique. Serum levels (mcg/ml) at 12 and 24 hours after the loading dose were 18.9 + 3 and 18.6 2 3.1
If the infant responded with the expected therapeutic serum level, and if the abstinence score decreased to <8 (defined as control of symptoms), maintenance doses were begun. Daily maintenance dosing of 2 mg/kg/day allowed serum levels to decline at a desirable rate of 20% per day. These infants were more easily controlled and detoxified with the phenobarbital loading dose method than with previously accepted dosing regimens.
Supported by NIDA Grant llDA01807 and Commonwealth of Pa. Contract 61674.
Department Pediatrics, Denver.
Serial plasma levels of furosemide were measured in 14 prenature newborns by high-pressure liquid chromatography following an intravenous dose of 1 mg/kg. All neonates were less than 21 days of age with birth weights ranging from 700 to 2500 grams. The half-life for furosemide calculated from the elintination rat, constant was 19.95 t 3.0 hours (mean f s. err.) in these infants The plasm clearance was determined to be 10.58 t 2.1 ml/kg/hour Equilibrium dialysis revealed more than 90% protein binding of furosemide by the newborn. The volume of distribution measured from the kinetic data was 0.24 f .03 L/kg and is consistent with extensive binding of furosemide within the vasculature. Several infants were re-studied and found to have an adult half-life by four months of age.
No correlation was observed between birth weight or postnatdl age and the elimination of furosemide within the group studied.
These data are very different from those reported for either adults or older children and indicate that the frequency for ad-'nistration of furosemide to the newborn withln the first three eeks of life should be no more than twice daily if drug accumlation is to be avoided. Furthermore, the prolonged half-life f furosemide in the newborn may contribute to altered elimintion or toxicity of other drugs (e.g., aminoglycosides) in this qe-group. 
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We previously reported thar human growth i~ormone (hGH) ~ltcrs drug metabolism when administered to growth hormone deficient children. Six weeks of t.i.w. administration of 2U i.m. was found to increase half-life (t'l) of amobarbital from 13.9 lirs tu 22.8 hrs. Further investigations on hcli deficient children were undertaken to elucidate the possible rule of h ( : l i in regulation of hepatic drug oxidation. Amobarbital was again chosen as 2 representative substrate. Pharmacokinetic parameters (Vd, tIl, C1) were determined on the basis of at least 3 blood lcvel measurements following a single 3 -5 mglkg oral dose. 111 three children amobarbital was given before and 12 hrs after a single injection of 2U of hCH. No significant change in Vd, ti or C1 was found. One subject was restudied at 6 weeks and found to have the characteristic prolongation of t$ at that time. Two children were studied before and after 4 injections of hGH on alternate days. One showed no change in drug elimination; the other showed a very slight increase in t'l. 1\11 children who showed a prolongation at 6 weeks and who were restudied 12 or more months later continued to have a long t'2. Conclusions: (1) The hCH inhibition of amobarbital metabolism is reproducible (2) the effect is not evident at 2 weeks but is complete by 6 weeks, at least on current treatment schedules and ( 3 ) the effect persists for one year of treatment or longer; diminution a f -ṽ d 407
